Patent ID: 7939295

Claim:
A method for the production of an immunogenically modified protein or polypeptide having a specific biological activity and being substantially non-immunogenic or less immunogenic than any non-modified target protein or polypeptide having the same biological activity when used in vivo, the method comprising the following steps: (i) determining the amino acid sequence of at least a portion of a target protein or polypeptide; (ii) identifying at least one potential T-cell epitope on said sequence having the potential to bind the HLA-DR allotypes to which the polypeptide of SEQ ID NO: 1 binds using standard methods; (iii) modifying the target protein or polypeptide by introducing at the C-terminus or N-terminus of the target protein or polypeptide one or more copies of a peptide of sequence AILEFRAMAQFSRKTD (SEQ ID NO: 1), wherein the peptide of sequence AILEFRAMAQFSRKTD (SEQ ID NO: 1) is attached to the C-terminus or N-terminus by a protease cleavage site involved in the MHC class II processing pathway.